전체 프로그램

ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved1,132 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

AntibodyLimited DatastaleLei LiuPhase 2

MRG003 combined with Pucotenlimab (MRG003 combined with Pucotenlimab)

Head and Neck Squamous Cell Carcinoma (HNSCC) · Head and Neck Squamous Cell Carcinoma (H

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase2#monoclonal-antibody#Lei
Trials 1Status Recruiting
AntibodyLimited DatastaleLei LiuPhase 2

MRG003 combined with Pucotenlimab+Cisplatin (MRG003 combined with Pucotenlimab+Cisplatin)

Head and Neck Squamous Cell Carcinoma (HNSCC) · Head and Neck Squamous Cell Carcinoma (H

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase2#monoclonal-antibody#Lei
Trials 1Status Recruiting
AntibodyLimited DatastaleMyeloid TherapeuticsPhase 1

atezolizumab (Tecentriq, MT-303 +Atezolizumab + Bevacizumab)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase1#monoclonal-antibody#Myeloid
Trials 1Status Recruiting
CGTLimited DatastaleCelladon CorporationPhase 2

MYDICAR Phase 1 (MYDICAR Phase 1)

Ischemic Cardiomyopathy; Non-ischemic Cardiomyopathy · Ischemic Cardiomyopathy

#IschemicCardiomyopathy#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Discontinued
CGTLimited DatastaleCelladon CorporationPhase 2

MYDICAR Phase 2 (MYDICAR Phase 2)

Ischemic Cardiomyopathy; Non-ischemic Cardiomyopathy · Ischemic Cardiomyopathy

#IschemicCardiomyopathy#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Discontinued
CGTLimited DatastaleEssen BiotechPhase 2

Mesothelin and Claudin 18.2 CAR-T cells (Mesothelin and Claudin 18.2 CAR-T cells)

Pancreatic Cancer; Pancreatic Carcinoma · Pancreatic Cancer

#PancreaticCancer#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleLeman Biotech Co., Ltd.Phase 1

Metabolically Armed BCMA CAR-T cells. (Metabolically Armed BCMA CAR-T cells.)

Multiple Myeloma (MM); Plasma Cell Leukemia (PCL) · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleLeman Biotech Co., Ltd.Phase 1

Metabolically Armed CD19 CAR-T cells (Metabolically Armed CD19 CAR-T cells)

Diffuse Large B-cell Lymphoma · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleSecond Affiliated Hospital, Sch…Phase 1

Metabolically Armed EGFRvIII CAR-T cells (Metabolically Armed EGFRvIII CAR-T cells)

Glioblastoma (GBM) · EGFR

#EGFR#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleXuzhou Medical UniversityPhase 2

Mixed CAR-T Transfer (Mixed CAR-T Transfer)

Hematopoietic/Lymphoid Cancer · Hematopoietic/Lymphoid Cancer

#HematopoieticLymphoidCancer#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleShanghai Longyao Biotechnology …Phase 2

Mixed CD19/CD20 CAR-T Transfer (Mixed CD19/CD20 CAR-T Transfer)

Recurrent or Refractory B Cell Malignancy · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleLiqun ZouPhase 1

Modified anti-CD19 CAR T cells (Modified anti-CD19 CAR T cells)

Refractory B-Cell Non-Hodgkin Lymphoma; Refractory Leukemia · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
AntibodyLimited DatastaleMayo ClinicPhase 2

Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine (Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine)

Fallopian Tube Carcinosarcoma; Primary Peritoneal Carcinosarcoma · Fallopian Tube Carcinosarcoma

#FallopianTubeCarcinosarcoma#Antibody#Phase2#monoclonal-antibody#PrimaryPeritonealCarcinosarcoma+1
Trials 1Status Recruiting
CGTLimited DatastaleShenzhen Geno-Immune Medical In…Phase 2

NG2 and DLL3 CAR-T cells (NG2 and DLL3 CAR-T cells)

Melanoma · Melanoma

#Melanoma#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Discontinued
CGTLimited DatastaleChongqing Sidemu BiotechPhase 2

NK cells,IL15-NK cells,NKG2D CAR-NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells (NK cells,IL15-NK cells,NKG2D CAR-NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells)

COVID-19 · COVID-19

#COVID-19#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Active
CGTLimited DatastaleZhejiang UniversityPhase 1

NKG2D CAR NK and NKG2D CAR T cells (NKG2D CAR NK and NKG2D CAR T cells)

Patients With Advanced Solid Tumors With Liver Metastases Who Have Failed Standard Treatments · Patients With Advanced Solid Tumors With

#PatientsWithAdvancedSolidTumorsW#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleZhejiang Provincial People's Ho…Phase 2

NKG2D CAR-NK with PD-1 Antibody (NKG2D CAR-NK with PD-1 Antibody)

Anaplastic Throid Carcinoma · PD-1

#PD-1#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleKAEDIPhase 1

NKG2D-based CAR T-cells (NKG2D-based CAR T-cells)

Hepatocellular Carcinoma; Glioblastoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleCelyad Oncology SAPhase 1

NKR-2 CAR-T Cells (NKR-2 CAR-T Cells)

AML, Adult; Myelodysplastic Syndromes · AML, Adult

#AMLAdult#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Discontinued
CGTLimited DatastaleNkarta, Inc.Phase 1

NKX101 - CAR NK cell therapy (NKX101 - CAR NK cell therapy)

Relapsed/Refractory AML; AML, Adult · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting

44 / 57 pages

← PreviousNext →